Topoisomerase IIα as a prognostic factor in pituitary tumors

Trofimiuk–Müldner, Małgorzata; Bałdys-Waligórska, Agata; Sokołowski, Grzegorz; Adamek, Dariusz; Hubalewska‐Dydejczyk, Alicja; Gołkowski, Filip

doi:10.20452/pamw.2454

Cited by 4 publications

(12 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Local invasion and infiltration of the adjacent structures, postoperative regrowth or persistence of hormonal function are potential indicators of PA aggressiveness [11,13,21,22]. In our study Ki-67 and TOPO 2A indices were significantly higher in invasive vs. non-invasive somatotropinomas.…”

Section: Invasivenesssupporting

confidence: 54%

“…In a group of predominantly non-functioning adenomas, Ki-67 indices ranged from 1% to 4.8% [24] and from 1.4% to 5.2% in somatotropinomas [25]. TOPO 2A-positive immunostaining in our somatotropinomas was higher than that in patients with different types of PAs [11,13], where values of the TOPO 2A index ranged from 0% to 3.5%, with a median value of about 0.7% [13,26], against our median LI of 1.5%.…”

Section: Prace Oryginalnementioning

confidence: 54%

“…In other studies of GH-secreting adenomas, Ki-67 index depended on gender but not on patient age [32]. Results concerning TOPO 2A expression are generally inconclusive: Vidal et al [11] found negative correlation between TOPO 2A expression and patient age and no correlation with patient gender, while elsewhere TOPO 2A expression did not depend on patient age [13,14]. Age and gender and adenoma type did not affect AIP [18] and VEGF expression [31].…”

Section: Age and Gendermentioning

confidence: 88%

“…However, lack of correlation between Ki-67 expression and tumour size was also reported [8]. Elsewhere, higher TOPO 2A expression was shown in non-functioning macroadenomas, which correlated with tumour size [13], while no correlation between TOPO 2A expression and tumour size [14], or even negative correlation [11] were also observed. A low AIP score was found in large somatotropinomas [33].…”

Section: Tumour Sizementioning

confidence: 98%

“…TOPO 2A is one of the key enzymes in DNA replication and cell division [10], indicating rapid cell proliferation in many tumours [11][12][13]. In PAs, strong correlation between MIB1 and TOPO 2A expression was found [13].…”

Section: Prace Oryginalnementioning

confidence: 99%

See 4 more Smart Citations

Markery Proliferacji I Inwazyjności W Guzach Przysadki Wydzielających Hormon Wzrostu

Bałdys-Waligórska

Wierzbicka

Sokołowski

et al. 2015

Endokrynologia Polska

Self Cite

View full text Add to dashboard Cite

Introduction: In the search for markers of invasiveness of pituitary adenomas, we studied the expression of Ki-67 antigen, TOPO 2A (topoisomerase 2 alpha), AIP (Aryl Hydrocarbon Receptor-Interacting Protein), and VEGF (Vascular Endothelial Growth Factor) in somatotropinomas. Material and methods:We retrospectively studied a group of 31 patients who underwent pituitary tumour surgery. Expression of Ki-67, TOPO 2A, AIP, and VEGF in surgical specimens was determined by immunohistochemistry. Relations between quantitatively determined markers and clinical symptoms, tumour features, and MR imaging, were analysed. Acromegaly was confirmed by hormonal tests in all patients studied. Local invasiveness (cavernous sinus penetration, optic chiasm compression or suprasellar extension) was observed in 18/31 patients (58.1%).

show abstract

Section: Invasivenesssupporting

confidence: 54%

Section: Prace Oryginalnementioning

confidence: 54%

Section: Age and Gendermentioning

confidence: 88%

Section: Tumour Sizementioning

confidence: 98%

Section: Prace Oryginalnementioning

confidence: 99%

See 3 more Smart Citations

Markery Proliferacji I Inwazyjności W Guzach Przysadki Wydzielających Hormon Wzrostu

Bałdys-Waligórska

Wierzbicka

Sokołowski

et al. 2015

Endokrynologia Polska

Self Cite

View full text Add to dashboard Cite

show abstract

Prothymosin alpha and Ki-67 expression in pituitary adenomas

Gołkowski¹,

Wierzbicka-Tutka²,

Sokołowski³

et al. 2014

EJEA

Self Cite

View full text Add to dashboard Cite

Prothymosin alpha (PTMA), a nuclear oncoprotein involved in cell cycle regulation, is used as a prognostic marker in many cancers. The histopathology of pituitary carcinomas and locally invasive adenomas is indistinguishable from that of benign tumors. A new marker is needed to differentiate these lesions. We evaluated PTMA in pituitary adenomas to determine its usefulness as a prognostic factor of tumor proliferation. We conducted a retrospective analysis of a group of 27 patients, including 15 females (56%) and 12 males (44%) with a mean age of 58.6±12 years, who underwent pituitary tumor surgery between 2003 and 2012. The Ki-67 and PTMA-nuclear (PTMA-n) and PTMA-cytoplasmic (PTMA-c) indices were determined by immunohistochemical staining. We studied histopathological features, clinical symptoms, and magnetic resonance imaging or computed tomography performed before surgery and one year following surgery to evaluate tumor size and progression. The expression of Ki-67 was revealed in 77.8% of adenomas, PTMA-n in 81.5% and PTMA-c in 92.6%. The mean value of the Ki-67 index was 1.8%, PTMA-n was 1.84%, and PTMA-c was 35.6%. There was a significant positive correlation between Ki-67 and PTMA-n (p=0.009). We did not find any correlation between Ki-67, PTMA-c, and tumor progression. PTMA-n was found to be correlated with tumor size (p=0.045) and was higher in the case of gonadotropinomas (p=0.026). The positive nuclear expression of Ki-67 and PTMA was observed in the majority of pituitary adenomas. Neither the expression of Ki-67 nor that of PTMA-c was related to tumor recurrence or local invasion.

show abstract